...
首页> 外文期刊>Annals of Surgery >Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases.
【24h】

Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases.

机译:肝切除术后复发性肝和/或肺转移对大肠转移的生存获益的队列研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To evaluate resection for hepatic and/or pulmonary recurrences in a cohort that underwent initial hepatectomy for colorectal liver metastases. SUMMARY BACKGROUND DATA: The survival benefit of repeated resections for hepatic and/or pulmonary recurrences after initial hepatectomy for colorectal liver metastases has remained unclear. METHODS: Recurrence occurred in 166 of the 216 patients after the first hepatectomy. Repeated resections were performed in 98 patients. We investigated the pattern of recurrence, the proportion of patients who underwent repeated resection, and the surgical outcome. RESULTS: Of the 166 patients with recurrence, 71 had isolated hepatic recurrence, 25 had isolated pulmonary recurrence, 13 had hepatic plus pulmonary recurrence, and 57 had recurrence in other organs. Repeated resections were conducted in 60 (85%) patients with isolated hepatic recurrence, 21 (84%) with isolated pulmonary recurrence, and 9 (69%) with both hepatic and pulmonary recurrence. The 5-year survival rates after repeated resection were 39%, 37%, and 20% for isolated hepatic recurrence, isolated pulmonary recurrence, and hepatic plus pulmonary recurrence, respectively. Multivariate analysis revealed that the following variables contributed to poor prognosis (hazard ratio [95% confidence interval]): number of recurrent tumors (1.20 [1.11-1.29]), maximum size of recurrent tumors (1.26 [1.02-1.48]), pulmonary recurrence (2.36 [1.41-3.20]), and hepatic plus pulmonary recurrence (4.01 [2.86-.17]). CONCLUSIONS: Patients with pulmonary or hepatic plus pulmonary recurrence had poorer prognoses than those with isolated hepatic recurrence. Reresection is the only potentially curative treatment. Stricter indication criteria, especially regarding the number of tumor nodules, can lead to comparable long-term outcomes.
机译:目的:评估在接受初次肝切除术治疗大肠肝转移的队列中肝和/或肺复发的切除术。摘要背景资料:初次肝切除术治疗结直肠肝转移后,肝和/或肺复发的重复切除术的生存获益尚不清楚。方法:216例患者中有166例在第一次肝切除术后复发。 98例患者进行了重复切除。我们调查了复发模式,接受了反复切除的患者比例以及手术结局。结果:166例复发患者中,单纯肝复发71例,单纯肺复发25例,肝加肺复发13例,其他器官复发57例。在60例(85%)的孤立性肝复发,21例(84%)的孤立性肺复发和9例(69%)肝和肺复发的患者中进行了重复切除。反复切除后的5年生存率分别为单纯性肝复发,单纯性肺复发和肝加肺复发。多因素分析显示,以下变量可导致不良预后(危险比[95%置信区间]):复发肿瘤数量(1.20 [1.11-1.29]),复发肿瘤最大尺寸(1.26 [1.02-1.48]),肺复发(2.36 [1.41-3.20])和肝加肺复发(4.01 [2.86-.17])。结论:肺或肝合并肺复发的患者的预后较单纯肝复发的患者差。切除是唯一可能治愈的方法。更严格的适应症标准,尤其是关于肿瘤结节的数目,可以导致相当的长期结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号